tbuckley/cabot-search huggingface dataset:
Nature, London
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical Studies of Neuropathy Due to Macroglobulinemia (Waldenström's Syndrome)
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hantavirus Pulmonary Syndrome—Panama, 1999-2000
Journal: JAMA (2000)

Hantavirus pulmonary syndrome (HPS) is an acute viral rodentborne zoonosis characterized by severe cardiopulmonary illness with a 40%-60% case-fatality rate. Since its identification in the United States in 1993, the recognized clinical spectrum of illnesses associated with human hantavirus infection has expanded to include mild illness, and case-patients have been identified in Canada and South America. This report describes the first confirmed HPS cases from Central America and summarizes preliminary results of clinical, epidemiologic, and ecologic investigations. Investigators identified 12 suspected cases with typical disease and captured four common species of rodents near case households.
Transplantation of HL-A Identical Allogeneic Bone Marrow to a Patient With Acute Lymphocytic Leukemia
Authors: ROBERT G. GRAW, JAMES A. BROWN, RONALD A. YANKEE, BRIGID G. LEVENTHAL, JACQUELINE WHANG-PENG, G. NICHOLAS ROGENTINE, EDWARD S. HENDERSON
Journal: Blood (1971)
Eating Walnuts Lowers Cholesterol Levels in People with High Cholesterol
Journal: Annals of Internal Medicine (2000)

Summaries for Patients4 April 2000Eating Walnuts Lowers Cholesterol Levels in People with High CholesterolSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-7-200004040-00039 SectionsAboutFull Text ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?High cholesterol (hypercholesterolemia) is a risk factor for heart disease. Drug treatments are available that can help to lower cholesterol levels. However, diet is a major part of treatment for everyone with high cholesterol levels and is often the only recommended preventive treatment for people who have not yet developed heart disease. One way to lower cholesterol is to change the fat content of diets by substituting polyunsaturated fat (which is mostly from vegetable oils and does not increase cholesterol) for saturated fat (which is mostly from animal ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Substituting Walnuts for Monounsaturated Fat Improves the Serum Lipid Profile of Hypercholesterolemic Men and Women. A Randomized Crossover Trial.”. It is in the 4 April 2000 issue of Annals of Internal Medicine (volume 132, pages 538-546). The authors are D. Zambón, J. Sabaté, S. Muñoz, B. Campero, E. Casals, M. Merlos, J.C. Laguna, and E. Ros.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSubstituting Walnuts for Monounsaturated Fat Improves the Serum Lipid Profile of Hypercholesterolemic Men and Women Daniel Zambón , Joan Sabaté , Sonia Muñoz , Betina Campero , Elena Casals , Manuel Merlos , Juan C. Laguna , and Emilio Ros Metrics 4 April 2000Volume 132, Issue 7Page: 538KeywordsCardiovascular therapyCholesterolDietEatingFatsHypercholesterolemiaLongitudinal studiesMeatMedical risk factorsOils ePublished: 15 August 2000 Issue Published: 4 April 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.Loading ...
β‐Globin gene haplotype in Hb SC disease
Authors: Martin H. Steinberg, Ronald L. Nagel, Christine Lawrence, Venkataramani Swaminathan, Zhi‐Hong Lu, Maria Plonczynski, Audrey Harrell
Journal: American Journal of Hematology (1996)

We asked the question, is the haplotype found with the sickle hemoglobin gene associated with different hematological characteristics in patients who were combined heterozygotes for sickle hemoglobin and hemoglobin C (Hb SC disease)? In 73 adults with Hb SC disease, a Benin haplotype chromosome was present in 56%, and Bantu (or Central African Republic; CAR), Senegal, and atypical haplotype chromosomes were found in 25%, 6%, and 12%, respectively. No significant differences were found in hematological characteristics or fetal hemoglobin levels of patients with Benin/C, CAR/C, Senegal/C, and atypical/C haplotypes. There were 71%C I, 18% C II, and 11% other βc haplotypes. Fetal hemoglobin levels are lower in Hb SC disease than in sickle-cell anemia. Perhaps because haplotype has no discernible effect on fetal hemoglobin level in Hb SC disease, it does not modulate its hematological features. © 1996 Wiley-Liss, Inc.
TOLBUTAMIDE AND GASTRIC SECRETION
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 14303: Low Global Longitudinal Strain in Ischemic Cardiomyopathy Patients at Baseline is Associated With Ventricular Arrhythmias After Cardiac Resynchronization Therapy
Authors: Bhupendar Tayal, Antonia Delgado-Montero, Akiko Goda, Samir Saba, Niels Risum, Peter Sogaard, John Gorcsan
Journal: Circulation (2015)

Introduction: Heart failure (HF) patients have an increased risk for ventricular arrhythmias (VA) and in particular patients with ischemic cardiomyopathy (ICM) have a worse prognosis after cardiac resynchronization therapy with defibrillator (CRT-D) compared with non-ischemic patients. Hypothesis: We hypothesize that global longitudinal strain (GLS) at baseline has the ability to identify ICM patients at higher risk for VA after CRT-D. Methods: We prospectively studied 175 consecutive HF patients implanted with CRT-D from a single center. All of them had class II-IV HF symptoms, LV ejection fraction (≤35%), QRS≥120 ms. GLS was measured from the three standard apical views and presented as absolute values. Outcome event was defined as VA (anti-tachycardia pacing or appropriate shock) after CRT in the first 2 years of follow-up. Results: Of 175 patients aged 65±11 years, 135 (77%) were male and 115 (66%) had ICM. They suffered 34 (19%) VA events over 2 years. Mean GLS of the population was 8.1±3.0. GLS (&lt; 6.5%) was associated with VA events after CRT-D with a sensitivity of 70% and specificity of 56%. A cutoff of GLS&lt;6.5% was associated with greater VA events in the ICM patients with HR 2.92 (95% confidence interval 1.48 to 5.77, p=0.002). A similar significant association of GLS was not seen in the non ICM patients (p=0.12). Conclusions: Low GLS (&lt;6.5% in absolute values) in ICM patients is associated with increased risk for VA after CRT-D and might represent more extensive myocardial scarring and has prognostic implications.
Authors’ Reply
Authors: William G. Herrington, Killian Donovan, Borislava Mihaylova
Journal: Journal of the American Society of Nephrology (2018)

The published observational data show similarly sized epidemiologic associations between increased fibroblast growth factor-23 (FGF-23) concentration and risk of a range of cardiovascular (atherosclerotic and nonatherosclerotic) and noncardiovascular outcomes. There is also an absence of any clear exposure-response relationship.1 Pelletier and Fouque2 have hypothesized that Klotho modifies FGF-23 associations with cardiovascular outcomes, and confirmation in large-scale studies is of interest. Such analyses, however, are unlikely to provide an explanation for the nonspecificity of FGF-23 associations. Instead, as recommended by Zhou et al.,3 further mechanistic experiments are needed. We suggest that such studies include the full range of noncardiovascular outcomes identified as associated with FGF-23. In the absence of good mechanistic evidence clearly supporting FGF-23’s role in a much wider range of disease processes, residual confounding is currently the most plausible explanation for the nonspecific associations. The epidemiology is suggesting the relationship between FGF-23 and cardiovascular disease risk may not be one of cause and effect. Disclosures None.
Narkose zu operativen Zwecken
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Celiac Disease Diagnosis and Management: A 46-Year-Old Woman With Anemia
Authors: D. Leffler
Journal: JAMA (2011)

Celiac disease is one of the most prevalent autoimmune gastrointestinal disorders, but as the case of Ms J illustrates, diagnosis is often delayed or missed. Based on serologic studies, the prevalence of celiac disease in many populations is estimated to be approximately 1% and has been increasing steadily over the last 50 years. Evaluation for celiac disease is generally straightforward and uses commonly available serologic tests; however, the signs and symptoms of celiac disease are nonspecific and highly heterogeneous, making diagnosis difficult. Although celiac disease is often considered a mild disorder treatable with simple dietary changes, in reality celiac disease imparts considerable risks, including reduced bone mineral density, impaired quality of life, and increased overall mortality. In addition, a gluten-free diet is highly burdensome and can profoundly affect patients and their families. For these reasons, care of individuals with celiac disease requires prompt diagnosis and ongoing multidisciplinary management.
Educational requirements for American Board of Internal Medicine
Authors: P. H. Futcher
Journal: JAMA (1969)

On June 10, 1969, the American Board of Internal Medicine resolved to initiate changes in its educational requirements for examination, and in the timing of its examinations, which it has had under consideration for the past year. Candidates who have completed a minimum of two full years of postdoctoral education in internal medicine will be admitted to a "qualifying examination" provided they are engaged in a third year of postdoctoral education in internal medicine or a related field at the time that they undertake that examination. Candidates who are successful in the qualifying examination and have provided evidence that they have completed the required three postdoctoral years of education will be awarded a certificate attesting to these accomplishments. This certificate is proposed as the qualifying agent for many physicians preparing themselves for the practice of internal medicine with the goal of serving as a general internist or primary physician. During
The NIEHS Superfund Basic Research Program: Overview and Areas of Future Research Directions
Authors: William A. Suk
Journal: Environmental Health Perspectives (1995)

Program is currently funding 142 separate research projects within 18 programs encompassing 29 universities and institutions around the United States.The research under this program covers a wide range of interdisciplinary science from both the biomedical and nonbiomedical perspectives.This is a unique program of technology-driven research.Nonetheless, there are some areas of research that should be investigated or investigated further, should funds become available.Environmental health risk posed by the location of Superfund sites may be distributed inequitably across socioeconomic status and racial groups.Since one in five children now lives below the poverty line, an important aspect of environmental equity must be the investigation of the health effects of environ- mental factors on children.The multidisciplinary investigation of the effects of hazardous substance exposure on children is an area that needs much research due to the fact that most of the toxicologic data available are based on adults and animals.This program is funding 27 projects on ecologic damage posed by hazardous wastes.Much more research is needed in the investigation of toxic effects on natural succession of ecosystems as well as on their effects on biodiversity to further our understanding of the food web in the role of bioavailability in human health, and to examine the bioaccumulation of these chemicals as it relates to their fate and transport.This program is researching and developing many innovative technolo- gies for detecting, assessing, and reducing toxic materials in the environment.As these products are developed through basic research, it becomes necessary to design a technology-transfer strategy for this program to handle the unique problems associated with transferring multidisciplinary technology from basic research to applied research and eventually to technology demonstrations and commercialization.Two areas of prime consid- eration are biologically based risk assessment and bioremediation.Presently, more than half of hazardous waste remediation is done via incineration.Additional funding will allow for investigating innovative technologies in incineration, to augment studies on the health effects of exposure to toxic combustion by-products, and to develop real-time monitors for hazardous waste incinerator emissions.From a public health perspective, this tech- nology may allow for the destruction of environmental hazardous wastes such that potential human health effects are ameliorated, or indeed pre- vented, specifically by reducing the amount and toxicity of hazardous substances.
International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Oceania and South East Asia
Authors: Isabelle Ethier, David W. Johnson, Aminu K. Bello, Feng Ye, Mohamed A. Osman, Adeera Levin, David C.H. Harris, Peter Kerr, Adrian Liew, Muh Geot Wong, Meaghan Lunney, Syed Saad, Deenaz Zaidi, Maryam Khan, Vivekanand Jha, Marcello Tonelli, Ikechi G. Okpechi, Andrea K. Viecelli
Journal: Kidney International Supplements (2021)
PLoS Medicine Issue Image | Vol. 6(9) September 2009
Journal: PLoS Medicine (2009)

In this month's Editorial the PLoS Medicine Editors discuss the importance of valid negative results, and their immediate and open availability, in maintaining the integrity of the medical literature, especially when clinical effectiveness is at issue. The Editorial suggests that physicians mindful of Hippocrates's vow "first do no harm" should appreciate that a study "that questions the accepted or desired way of doing things can be at least as important as one that supports a new approach." Given the US movement to undertake comparative effectiveness research (CER)—which calls for a wide range of study designs to "assist consumers, clinicians and policy-makers in making informed decisions"—the Editorial argues for transparency in the design and reporting of all types of research, including data that cast doubt on prevailing practices. Image Credit: Image adapted from photograph by Tony Fischer, Carpe Diem Photography, at flickr.com
THE EVOLUTIONARY ASPECT OF INFECTIOUS DISEASES, WITH ESPECIAL REFERENCE TO THE LOCAL VENEREAL DISEASES.
Authors: G. FRANK LYDSTON
Journal: JAMA (1902)

The light factor of environment is very important in the life history of micro-organisms. In general, bacteria flourish and wax fat in the absence of light. To many pathogenic micro-organisms light—especially direct sunlight—is fatal. In rare instances, as in the case of Englemann's bacterium photometricum, light increases activity. I know of no pathogenic germs in which the reverse does not prevail in greater or less degree. That temperature is an important factor in micro-organic life is so familiar that I would not allude to it were it not so vital in its relations to the evolution of infection. Bacteria have been found that multiply at 0 C. Certain water varieties spore in water covered with ice and freezing does not kill them, but most soil and water bacteria thrive best at about 20 C. although they begin to multiply at a lower point. Germs have been found which grow only
A phase II study of intermittent sunitinib (S) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC).
Authors: Brian I. Rini, Laura S. Wood, Paul Elson, Hui Zhu, Namita Chittoria, Kriti Mittal, Robert Dreicer, Timothy D. Gilligan, Shetal N. Shah, Jorge A. Garcia
Journal: Journal of Clinical Oncology (2013)

4515 Background: S as initial treatment in mRCC is limited by balancing acute and chronic toxicity with clinical benefit. Pre-clinical and retrospective clinical data support that extended treatment breaks are feasible without a reduction in efficacy. Methods: Pts with treatment-naïve clear cell mRCC were enrolled on a prospective phase II trial and initially treated with 4 cycles of S (50 mg 4/2). Pts with ≥ 10% reduction in tumor burden (TB) following 4 cycles had S held, with CT scans approximately every 10 weeks. S was re-initiated for 2 cycles in those pts with an increase in TB by ≥ 10% and again held with ≥ 10% TB reduction. This intermittent S dosing continued until RECIST-defined disease progression while on S. The primary objective was feasibility of intermittent S, defined as the proportion of eligible pts who underwent intermittent therapy. The alternative hypothesis was a feasibility of &gt; 80% vs. a null hypothesis of &lt; 50% (a=0.05; power 80%). Results: Thirty-six pts were enrolled; 70% male, median age 60, 95% PS 0/1 and 32% favorable/65% intermediate by Heng criteria. Twenty pts were eligible for intermittent therapy and all pts (100%) entered the intermittent phase. Pts were not eligible for intermittent S due to PD (n=13); toxicity (n=1) or w/d of consent (n=2) prior to end of cycle #4. Sixteen pts (80%) had ≥ 10% TB increase off S with a median (range) increase of 1.5 cm (1.1-2.5) compared to the TB immediately prior to stopping S, considering all off periods.Four pts did not have ≥ 10% TB increase off S (3 pts after the 1 st off period; off for 12, 8 and 5 months to date and 1 pt after the 2 nd off period; off for 8 months prior to restarting S). Most pts exhibited a stable saw tooth pattern of TB reduction on S and TB increase off S. No pt had RECIST-defined PD while on S, but 2 pts were taken off extended breaks due to gradual TB increase over time, and 1 pt developed new CNS mets during the 2 nd off period.The objective response rate was 53%. Toxicity was typical for S and completely resolved during treatment breaks. Conclusions: S dosing with periodic extended time off drug is feasible and associated with reduction in toxicity during the off periods. Clinical efficacy does not appear to be compromised. Clinical trial information: NCT01158222.